NA
CRSP icon

Navellier & Associates’s CRISPR Therapeutics CRSP Stock Holding History

Navellier & Associates’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,026
Closed -$247K – 308
2021
Q1 		$247K Hold
2,026
– – 0.04% 254
2020
Q4 		$310K Buy
+2,026
New +$239K 0.06% 221

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Navellier & Associates's CRSP Position: Q2 2021 in Review

Navellier & Associates sold out of CRISPR Therapeutics (CRSP) in Q2 2021, closing a stake of 2,026 shares — an estimated $247K sold.

Navellier & Associates first reported a position in CRSP in Q4 2020 and held it in 2 quarters. The position peaked at $310K in Q4 2020. 498 funds tracked by Wall St. Rank hold CRSP as of Q2 2021.

  • Navellier & Associates reported no remaining CRISPR Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Navellier & Associates sold 2,026 CRISPR Therapeutics shares in Q2 2021, an estimated $247K.
  • Navellier & Associates first reported a position in CRISPR Therapeutics in Q4 2020 and held it in 2 quarters.
  • Navellier & Associates's CRISPR Therapeutics position peaked at $310K in Q4 2020.
  • 498 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2021.

Based on Navellier & Associates's 13F filing for Q2 2021, filed 9 Aug 2021.